Semaglutide in Nonalcoholic Fatty Liver Disease
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05813249 |
Recruitment Status :
Completed
First Posted : April 14, 2023
Last Update Posted : April 2, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The goal of this clinical trial is to test the therapeutic effect of Semaglutide in NAFLD and its sequelae in obesity and/or type 2 diabetes mellitus. The main question it aims to answer is:
• Is the use of Semaglutide (oral or subcutaneous form) effective in improving NAFLD and its sequelae in obesity and/or type 2 diabetes mellitus?
Participants will undergo:
- Abdominal ultrasound.
- Fibroscan with controlled attenuation parameter to assess liver stiffness (kPa) and liver steatosis (dB/m).
- Fibrosis-4 score requires values of age, alanine aminotransferase, aspartate aminotransferase, and platelet count.
- NAFLD Fibrosis Score requires values of age, BMI, platelet count, albumin, hyperglycemia, and ALT/AST ratio.
Researchers will compare:
- Group 1 will receive oral Semaglutide for 48 weeks.
- Group 2 will receive injectable Semaglutide for 48 weeks.
- Group 3 will receive Pioglitazone and/or Vitamin E. to see if there is an improvement in liver stiffness and severity of hepatic steatosis after 48 weeks.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Non-alcoholic Fatty Liver Disease | Drug: Rybelsus Oral Product Drug: Ozempic Injectable Product Drug: Tocopherol and/or Actos | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 180 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Therapeutic Effect of Semaglutide on Nonalcoholic Fatty Liver Disease in Obesity and/or Type 2 Diabetes Mellitus |
Actual Study Start Date : | February 15, 2023 |
Actual Primary Completion Date : | February 15, 2024 |
Actual Study Completion Date : | April 1, 2024 |
Arm | Intervention/treatment |
---|---|
Active Comparator: NAFLD1
Hepatic steatosis
|
Drug: Rybelsus Oral Product
Oral Semaglutide |
Active Comparator: NAFLD2
Hepatic steatosis
|
Drug: Ozempic Injectable Product
Subcutaneous Semaglutide
Other Name: Wegovy |
Active Comparator: NAFLD3
Hepatic steatosis
|
Drug: Tocopherol and/or Actos
Vitamin E and/or Pioglitazone |
- NAFLD regression [ Time Frame: 48 weeks ]improvement of severity of hepatic steatosis evaluated by CAP (dB/m)
- Fibrosis regression [ Time Frame: 48 weeks ]improvement of liver stiffness evaluated by Fibroscan (kPa) and
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients diagnosed with NAFLD by non-invasive methods in the form of abdominal US or MRI, confirmed by a Fibroscan scan with CAP to assess the quantity of hepatic steatosis and severity of fibrosis up to 21 weeks before the start of the study and after treatment.
- Primary obesity with body mass index (BMI) > 30.
- Type 2 diabetes mellitus.
Exclusion Criteria:
- Type 1 diabetes mellitus.
- DM, which is treated with insulin glargine.
- Alcohol consumption.
- Patients had bariatric surgery.
- Hepatitis C virus, hepatitis B virus, HIV.
- Patients with peptic ulcer disease.
- Secondary obesity originated from hypothalamic or endocrinal disorders.
- Other causes of CLD.
- Decompensated liver disease.
- History of pancreatitis (acute or chronic).
- Hepato-biliary disorders.
- ALT and AST values > 5 times of upper normal limits.
- Severe cardiac disease.
- Patients treated with GLP-1 agonist within 90 days before screening.
- Patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05813249
Egypt | |
Zagazig University | |
Zagazig, Sharkia, Egypt, 44519 |
Principal Investigator: | Ayman Sadek, MD | Zagazig University |
Responsible Party: | Ayman Magd Eldin Mohammad Sadek, Associate Professor of Internal Medicine, Zagazig University |
ClinicalTrials.gov Identifier: | NCT05813249 |
Other Study ID Numbers: |
ZU-IRB#10461/15-2-2023 |
First Posted: | April 14, 2023 Key Record Dates |
Last Update Posted: | April 2, 2024 |
Last Verified: | April 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
Semaglutide Non-alcoholic Fatty Liver Disease Obesity Type 2 Diabetes Mellitus |
Liver Diseases Fatty Liver Non-alcoholic Fatty Liver Disease Digestive System Diseases Tocopherols Vitamin E Tocotrienols alpha-Tocopherol Semaglutide |
Antioxidants Molecular Mechanisms of Pharmacological Action Protective Agents Physiological Effects of Drugs Vitamins Micronutrients Glucagon-Like Peptide-1 Receptor Agonists Hypoglycemic Agents |